Vectura, which specialises in inhaled drug development solutions, has announced planning permission for a new 10,000 square metre facility in Bristol & Bath Science Park, which will become the company’s ‘Inhalation Centre of Excellence’.
The state-of-the-art £58 million building is set to be completed in 2025 and will enable Vectura to expand its operations, while providing new career opportunities for research and development scientists and engineers in pharmaceutical and device development, as well as manufacturing and laboratory services.
In constructing the new Inhalation Centre of Excellence, Vectura aims to create an optimal environment for innovation to support the development of important new inhaled treatments and wellness products. The company is also targeting the goal of achieving an ‘Excellent’ rating for the building with sustainability assessors BREEAM.
For nearly 25 years, Vectura has been providing a combination of formulation science, device technology and pharmaceutical development expertise, helping our partners and licensees develop products which are used by 10 million patients worldwide
Michael Austwick, Chief Executive Officer, Vectura, said: “We are delighted that our plans to build a world-leading science facility have been approved. The new-build will enable our already successful pharmaceutical company to continue and expand upon its vital work, providing innovative inhalation and other advanced drug delivery solutions that have the potential to improve the lives of patients around the world.”
Austwick continued: “For nearly 25 years, Vectura has been providing a combination of formulation science, device technology and pharmaceutical development expertise, helping our partners and licensees develop products which are used by 10 million patients worldwide. This new facility will help us to build on this successful track record, increasing workspace capacity and attracting talent to the area.”
Vectura currently has UK facilities in Chippenham and Cambridge, and helps partners to bring their medicines to market by drawing upon its specialist DPI, pMDI and nebuliser capabilities. Its combination of formulation science, device technology and inhaled development expertise has contributed to the success of 13 medicines.